Microtubule-targeted antitumor drugs: Chemistry, mechanisms and nanoparticle formulations

Gene Therapy and Molecular Biology

Volumn 12, Issue 2, 2008, Pages 313-358

  Boulikas, Teni ^a,b   Tsogas, Ioannis ^b  

^a Regulon Inc   (United States)

^b NONE   (Greece)

Author keywords

Abraxane; Aplidine; Colchicine; Cyclostreptin; Dictyostatin; Discodermolide; Docetaxel; Epothilones A, B, D; Griseofulvin; Ixabepilone; Microtubules; Nanoparticle; Nocodazole; P glycoprotein; Paclitaxel; Peloruside A; Sagopilone; Taxanes; Tubulin; Vinblastine; Vinca alkaloids; Vincristine; Vindesine; Vinflunine; Vinorelbine

Indexed keywords

MYXOCOCCALES; VINCA;

EID: 76949100241     PISSN: 15299120     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (249)

1. Advani R, Fisher GA, Lum BL, Jambalos C, Cho CD, Cohen M, Gollerkeri A, Sikic BI (2003) Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies. Clin Cancer Res 9, 5187-5194.
2. Albertsson P, Lennernäs B, Norrby K (2008) Dose effects of continuous vinblastine chemotherapy on mammalian angiogenesis mediated by VEGF-A. Acta Oncol 47, 293-300.
3. Alhamadsheh MM, Gupta S, Hudson RA, Perera L, Tillekeratne LM (2008) Total Synthesis and Selective Activity of a New Class of Conformationally Restrained Epothilones. Chemistry 14, 570-581.
4. Ali M, Mohammed N, Alnaqeeb MA, Hassan RA, Ahmad HS (1989) Toxicity of echinulin from Aspergillus chevalieri in rabbits Toxicol Lett 48(3), 235-41
5. Altmann KH, Gertsch J (2007) Anticancer drugs from nature--natural products as a unique source of new microtubulestabilizing agents. Nat Prod Rep 24, 327-357.
6. Amos LA, Kara S, Florenceb GJ, Patersonb I (2003) Discodermolide interferes with the binding of tau protein to microtubules. FEBS Lett 539, 34-36.
7. Aonuma M, Miyamoto M, Inoue YH, Tamai K, Sakai H, Kamasawa N, Matsukage A (2005) Microtubule bundle formation and cell death induced by the human CLASP/Orbit N-terminal fragment. Cell Struct Funct 30, 7-13.
8. Bai R, Edler MC, Bonate PL, Copeland TD, Pettit GR, Luduena RF, Hamel E (2008) Intracellular activation and deactivation of tasidotin, an analogue of dolastatin 15, correlation with cytotoxicity. Mol Pharmacol, in press.
9. Baiguera S, Conconi MT, Guidolin D, Mazzocchi G, Malendowicz LK, Parnigotto PP, Spinazzi R, Nussdorfer GG (2004) Ghrelin inhibits in vitro angiogenic activity of rat brain microvascular endothelial cells. Int J Mol Med 14, 849-854.
10. Baker SD, Zhao M, Lee CKK, Verweij J, Zabelina Y, Brahmer JR, et al (2004) Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10, 1976-1983.
11. Balog DM, Meng D, Kamanecka T, Bertinato P, Su DS, Sorensen EJ, Danishefsky SJ (1996) Total Synthesis of (-)-Epothilone A Angew Chem 108, 2976
12. Banerjee A (1997) Differential Effects of Colchicine and Its Bring Modified Analog MTPT on the Assembly-Independent GTPase Activity of Purified β-Tubulin Isoforms from Bovine Brain Biochem Biophys Res Commun 231, 698-700
13. Beer TM, Higano CS, Saleh M, Dreicer R, Hudes G, Picus J, Rarick M, Fehrenbacher L, Hannah AL (2007) Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs 25, 565-70.
14. Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, Schellens JH (2007) Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry. Invest New Drugs 25, 327-334.
15. Bifulco M, Laezza C, Stingo S, Wolff J (2002) 2',3'-Cyclic nucleotide 3'-phosphodiesterase, a membrane-bound, microtubule-associated protein and membrane anchor for tubulin. Proc Natl Acad Sci U S A 99, 1807-1812.
16. Blum JL, Dees EC, Chacko A, Doane L, Ethirajan S, Hopkins J, McMahon R, Merten S, Negron A, Neubauer M, Ilegbodu D, Boehm KA, Asmar L, O'Shaughnessy JA (2006) Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 24, 4384-4390.
17. Blum JL, Savin MA, Edelman G, Pippen JE, Robert NJ, Geister BV, Kirby RL, Clawson A, O'Shaughnessy JA (2007) Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 7, 850-856.
18. Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62, 6938-6943.
19. + channels through an Aktdependent signaling pathway in breast cancer cells, role in cell proliferation. J Cell Physiol 212, 690-701.
20. TM as a chemotherapy and antiangiogenesis drug. Cancer Ther 5, 351-376.
21. Boulikas T, Pantos A, Bellis E, Christofis P (2007) Designing platinum compounds in cancer, structures and mechanisms. Cancer Ther 5, 537-583.
22. Boulikas T, Stathopoulos GP, Volakakis N and Vougiouka M (2005) Systemic Lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res 25, 3031-3040.
23. Bragdon B, Bertone AL, Hardy J, Simmons EJ, Weisbrode SE (2001) Use of an isolated joint model to detect early changes induced by intra-articular injection of paclitaxel-impregnated polymeric microspheres. J Invest Surg 14, 169-182.
24. Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G (2006) Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity. Clin Cancer Res 12, 1760-1767.
25. Bröker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, Schellens JH, Giaccone G (2007) A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clin Cancer Res 13, 3906-3912.
26. Bromberg L (2008) Polymeric micelles in oral chemotherapy. J Control Release 128, 99-112.
27. Budillon A, Di Gennaro E, Bruzzese F, Rocco M, Manzo G, Caraglia M (2007) Histone deacetylase inhibitors, a new wave of molecular targeted anticancer agents. Recent Patents Anticancer Drug Discov 2, 119-134.
28. Buey RM, Calvo E, Barasoain I, Pineda O, Edler MC, Matesanz R, Cerezo G, Vanderwal CD, Day BW, Sorensen EJ, López JA, Andreu JM, Hamel E, Díaz JF (2007) Cyclostreptin binds covalently to microtubule pores and lumenal taxoid binding sites. Nat Chem Biol 3, 117-125.
29. Bullock K, Blackwell K (2008) Clinical efficacy of taxanetrastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 13, 515-525.
30. Cai S, Vijayan K, Cheng D, Lima EM, Discher DE (2007) Micelles of different morphologies--advantages of worm-like filomicelles of PEO-PCL in paclitaxel delivery. Pharm Res 24, 2099-2109.
31. Carayol N, Katsoulidis E, Sassano A, Altman JK, Druker BJ, Platanias LC (2008) Suppression of programmed cell death 4 (PDCD4) protein expression by BCR-ABL-regulated engagement of the mTOR/p70 S6 kinase pathway. J Biol Chem 283, 8601-8610.
32. Cardoso F, de Azambuja E, Lago LD (2008) Current perspectives of epothilones in breast cancer. Eur J Cancer 44, 341-352.
33. Carlson RO (2008) New tubulin targeting agents currently in clinical development. Expert Opin Investig Drugs 17, 707-722.
34. Caron JM, Herwood M (2007) Vinblastine, a chemotherapeutic drug, inhibits palmitoylation of tubulin in human leukemic lymphocytes. Chemotherapy 53, 51-58.
35. Carstens MG, de Jong PH, van Nostrum CF, Kemmink J, Verrijk R, de Leede LG, Crommelin DJ, Hennink WE (2008) The effect of core composition in biodegradable oligomeric micelles as taxane formulations. Eur J Pharm Biopharm 68, 596-606.
36. Cepeda V, Fuertes MA, Castilla J, Alonso C, Quevedo C, Soto M, Pérez JM (2006) Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Patents Anticancer Drug Discov 1, 39-53.
37. Cetto GL, Santo A, Genestreti G, Terzi A, Azzoni P, Sava T, Manno P, Molino A, Pattaro C, Micciolo R. (2006) Gemcitabine (GEM) and vindesine (VDS) in advanced nonsmall cell lung cancer (NSCLC), a phase II study in elderly or poor performance status patients. Lung Cancer 53, 355-360.
38. Chandran SS, Banerjee SR, Mease RC, Pomper MG, Denmeade SR (2008) Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA) Cancer Biol Ther 7, 974-982
39. Chang EH, Hwang SH, Rait A, Pirollo KF, Zhou Q, Yenugonda VM, Chinigo GM, Brown ML (2008) Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue. Mol Cancer Ther 7, 559-568.
40. Chaudhuri AR, Seetharamalu P, Schwarz PM, Hausheer FH, Ludueña RF (2000) The interaction of the B-ring of colchicine with alpha-tubulin, a novel footprinting approach. J Mol Biol 303, 679-692.
41. Chen J, Cui X, Zacharek A, Jiang H, Roberts C, Zhang C, Lu M, Kapke A, Feldkamp CS, Chopp M (2007) Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol 62, 49-58.
42. Chipman SD, Oldham FB, Pezzoni G, Singer JW (2006) Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymerdrug conjugate. Int J Nanomedicine 1, 375-383.
43. Chow LM, Nathan PC, Hodgson DC, Jenkin D, Weitzman S, Grant RM, Manson D, Bross A, Doyle JJ, Danjoux C, Greenberg ML (2006) Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation, J Clin Oncol 24, 5735-5741
44. Connors JM (2005) State-of-the-art therapeutics, Hodgkin's lymphoma. J Clin Oncol 23, 6400-6408.
45. Couladouros EA, Magos AD (2005) Solid-phase total synthesis of (-)-Phenylhistine and (-)-Aurantiamine. Synthesis of a diverse dehydro-2,5-diketopiperazine library. Part II Molecular Diversity 9, 111-121.
46. Couladouros EA, Magos AD (2005) Total asymmetric synthesis of (-)-Phenylhistine, (-)-Aurantiamine and related compounds. Part I Molecular Diversity 9, 99-109.
47. Crume KP, Miller JH, La Flamme AC (2007) Peloruside A, an antimitotic agent, specifically decreases tumor necrosis factor-alpha production by lipopolysaccharide-stimulated murine macrophages. Exp Biol Med (Maywood) 232, 607-613.
48. D'Agostino G, del Campo J, Mellado B, Izquierdo MA, Minarik T, Cirri L, Marini L, Perez-Gracia JL, Scambia G (2006) A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer. Int J Gynecol Cancer 16, 71-76.
49. Day BW, Ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, Rosenkranz HS (1996) Discodermolide, A Cytotoxic Marine Agent That Stabilizes Microtubules More Potently Than Taxol Biochemistry 35, 243-250
50. Desai N, Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res 11, 4136-4143
51. Desai NP, Trieu V, Hwang LY, Wu R, Soon-Shiong P, Gradishar WJ (2008) Improved effectiveness of nanoparticle albuminbound (nab) paclitaxel versus polysorbate-based docetaxel in multiple xenografts as a function of HER2 and SPARC status. Anticancer Drugs 19, 899-909.
52. Dong XF, Song Q, Li LZ, Zhao CL, Wang LQ (2007) Histone deacetylase inhibitor valproic acid inhibits proliferation and induces apoptosis in KM3 cells via downregulating VEGF receptor. Neuro Endocrinol Lett 28, 775-780.
53. du Bois A, Jung B, Loehr A, Schaller-Kranz T, Cohen M, Frickhofen N (2006) A phase I and pharmacokinetic study of novel taxane BMS-188797 and cisplatin in patients with advanced solid tumours. Br J Cancer 94, 79-84.
54. Edelman MJ (2006) Novel cytotoxic agents for non-small cell lung cancer. J Thorac Oncol 1, 752-755.
55. Edelman MJ, Gandara DR, Hausner P, Israel V, Thornton D, DeSanto J, Doyle LA (2003) Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer. Lung Cancer 39, 197-199.
56. El Hajj Dib I, Mélanie G, Valery S, Romuald M, Michel B, Kamel S. (2008) Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis. Leuk Res, in press.
57. Esmaeili F, Ghahremani MH, Ostad SN, Atyabi F, Seyedabadi M, Malekshahi MR, Amini M, Dinarvand R (2008) Folatereceptor-targeted delivery of docetaxel nanoparticles prepared by PLGA-PEG-folate conjugate. J Drug Target 16, 415-423.
58. Faneca H, Faustino A, Pedroso de Lima MC (2008) Synergistic antitumoral effect of vinblastine and HSV-Tk/GCV gene therapy mediated by albumin-associated cationic liposomes. J Control Release 126, 175-184.
59. Fang J, Nakamura H, Iyer AK (2007) Tumor-targeted induction of oxystress for cancer therapy. J Drug Target 15, 475-486.
60. Fenical W, Jensen PR, Kauffman C, Mayhead SL, Faulkner DJ, Sincich C, Rao MR, Kantorowski EJ, West LM, Strangman WK, Shimizu Y, Li B, Thammana S, Drainville K, Davies-Coleman MT, Kramer RA, Fairchild CR, Rose WC, Wild RC, Vite GD, Peterson RW (2003) New Anticancer Drugs from Cultured and Collected Marine Organisms Pharmaceutical Biology 41, 6-14
61. Ferrara N (2004) Vascular endothelial growth factor, basic science and clinical progress. Endocr Rev 25, 581-611.
62. Feyen F, Cachoux F, Gertsch J, Wartmann M, Altmann KH (2008) Epothilones as lead structures for the synthesis-based discovery of new chemotypes for microtubule stabilization. Acc Chem Res 41, 21-31.
63. Fialho AM, Chakrabarty AM (2007) Recent patents on bacterial proteins as potential anticancer agents. Recent Patents Anticancer Drug Discov 2, 224-234.
64. Fishman MN, Garrett CR, Simon GR, Chiappori AA, Lush RM, Dinwoodie WR, Mahany JJ, Dellaportas AM, Cantor A, Gollerki A, Cohen MB, Sullivan DM (2006) Phase I study of the taxane BMS-188797 in combination with carboplatin administered every 3 weeks in patients with solid malignancies. Clin Cancer Res 12, 523-528.
65. Florio T (2008) Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. Front Biosci 13, 822-840.
66. Forrest ML, Yáñez JA, Remsberg CM, Ohgami Y, Kwon GS, Davies NM (2008) Paclitaxel prodrugs with sustained release and high solubility in poly(ethylene glycol)-b-poly(ecaprolactone) micelle nanocarriers, pharmacokinetic disposition, tolerability, and cytotoxicity. Pharm Res 25, 194-206.
67. Fumoleau P, Coudert B, Isambert N, Ferrant E (2007) Novel tubulin-targeting agents, anticancer activity and pharmacologic profile of epothilones and related analogues. Ann Oncol Suppl 5, 9-15.
68. Garrett CR, Fishman MN, Rago RR, Williams CC, Dellaportas AM, Mahany JJ, Lush RM, Dalton WS, Gollerkeri A, Cohen MB, Sullivan DM (2005) Phase I study of a novel taxane BMS-188797 in adult patients with solid malignancies. Clin Cancer Res 11, 3335-3341.
69. Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD (1999) Phase I study of liposomal vincristine. J Clin Oncol 17, 697-705.
70. Georgoulias V, Ardavanis A, Tsiafaki X, Agelidou A, Mixalopoulou P, Anagnostopoulou O, Ziotopoulos P, Toubis M, Syrigos K, Samaras N, Polyzos A, Christou A, Kakolyris S, Kouroussis C, Androulakis N, Samonis G, Chatzidaki D (2005) Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer, a phase III randomized trial. J Clin Oncol 23, 2937-2945.
71. Gigant B, Wang C, Ravelli RB, Roussi F, Steinmetz MO, Curmi PA, Sobel A, Knossow M (2005) Structural basis for the regulation of tubulin by vinblastine. Nature. 435, 519-522.
72. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, Pavone V, Cavanna L, Santini G, Merli F, Liberati M, Baldini L, Deliliers GL, Angelucci E, Bordonaro R, Federico M; Intergruppo Italiano Linfomi (2005) ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma, final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23, 9198-9207.
73. Gómez-Varela D, Zwick-Wallasch E, Knötgen H, Sánchez A, Hettmann T, Ossipov D, Weseloh R, Contreras-Jurado C, Rothe M, Stühmer W, Pardo LA (2007) Monoclonal antibody blockade of the human Eag1 potassium channel function exerts antitumor activity. Cancer Res 67, 7343-7349.
74. Goodin S, Kane MP, Rubin EH (2004) Epothilones, mechanism of action and biologic activity. J Clin Oncol 22, 2015-2025.
75. Gradishar WJ (2006) Albumin-bound paclitaxel, a next-generation taxane. Expert Opin Pharmacother 7, 1041-1053.
76. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O'Shaughnessy J (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23, 7794-7803.
77. Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ (2006) Abraxane, a novel Cremophorfree, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 17, 1263-1268.
78. Gridelli C, Gallo C, Shepherd FA, Illiano A, Piantedosi F, Robbiati SF, Manzione L, Barbera S, Frontini L, Veltri E, Findlay B, Cigolari S, Myers R, Ianniello GP, Gebbia V, Gasparini G, Fava S, Hirsh V, Bezjak A, Seymour L, Perrone F (2003) Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer, a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 21, 3025-3034.
79. Gu YT, Zhang H, Xue YX (2007) Dexamethasone enhances adenosine 5'-triphosphate-sensitive potassium channel expression in the blood-brain tumor barrier in a rat brain tumor model. Brain Res 1162, 1-8.
80. Guo WJ, Tao GJ, Tao WY, Cui FJ, Jin XC, Bi F, Xu ZH, Ao ZH (2007) A myxobacterium strain Sorangium cellulosum AHB125 producing epothilone B and other anticancer substances. Nat Prod Res 21, 1256-1265.
81. Gupta, Jr. LM, Bode CJ, Georg, GI, Himes RH (2003) Understanding tubulin-Taxol interactions, Mutations that impart Taxol binding to yeast tubulin. Proc Natl Acad Sci USA 100, 6394-6397.
82. Haley B, Frenkel E (2008) Nanoparticles for drug delivery in cancer treatment. Urol Oncol 26, 57-64.
83. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, Muro K, Yamada Y, Okusaka T, Shirao K, Shimada Y, Nakahama H, Matsumura Y (2007) A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer 97, 170-176.
84. Hamaguchi T, Matsumura Y, Suzuki M, Shimizu K, Goda R, Nakamura I, Nakatomi I, Yokoyama M, Kataoka K, Kakizoe T (2005) NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel. Br J Cancer 92, 1240-1346.
85. Hamel E, Day BW, Miller JH, Jung MK, Northcote PT, Ghosh AK, Curran DP, Cushman M, Nicolaou KC, Paterson I, Sorensen EJ (2006) Synergistic effects of peloruside A and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly. Mol Pharmacol 70, 1555-1564.
86. Han LM, Guo J, Zhang LJ, Wang QS, Fang XL (2006) Pharmacokinetics and biodistribution of polymeric micelles of paclitaxel with Pluronic P123. Acta Pharmacol Sin 27, 747-753.
87. Hayashi Y, Orikasa S, Tanaka K, Kanoh K, Kiso Y (2000) Total Synthesis of Anti-microtubule Diketopiperazine Derivatives, Phenylahistin and Aurantiamine J Org Chem 65, 8402-8405
88. Henderson IC, Bhatia V (2007) Nab-paclitaxel for breast cancer, a new formulation with an improved safety profile and greater efficacy. Expert Rev Anticancer Ther 7, 919-943.
89. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23, 1011-1027.
90. Hiles JJ, Kolesar JM (2008) Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma. Am J Health Syst Pharm 65, 123-131.
91. Horti J, Juhasz E, Monostori Z, Maeda K, Eckhardt S, Bodrogi I (2008) Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer. Cancer Chemother Pharmacol 62, 173-180.
92. Horwitz SB, Klein LE, Freeze BS, Amos BS (2005) The microtubule stabilizing agent discodermolide is a potent inducer of accelerated cell senescence. Cell Cycle 4, 501-507.
93. Hsu LC, White RL (1998) BRCA1 is associated with the centrosome during mitosis. Proc Natl Acad Sci U S A 95, 12983-12988.
94. Huby RDJ, Weiss A, Ley SC (1998) Nocodazole Inhibits Signal Transduction by the T Cell Antigen Receptor J BiolChem 273, 12024 -12031
95. Huh KM, Min HS, Lee SC, Lee HJ, Kim S, Park K (2008) A new hydrotropic block copolymer micelle system for aqueous solubilization of paclitaxel. J Control Release 126, 122-129.
96. Hwang HY, Kim IS, Kwon IC, Kim YH (2008) Tumor targetability and antitumor effect of docetaxel-loaded hydrophobically modified glycol chitosan nanoparticles. J Control Release 128, 23-31.
97. Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, Nair MK, Bhar P, Desai N, Hortobagyi GN (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23, 6019-6026.
98. International Breast Cancer Study Group. (2006) Tamoxifen After Adjuvant Chemotherapy for Premenopausal Women With Lymph Node-Positive Breast Cancer, International Breast Cancer Study Group Trial 13-93. J Clin Oncol 24, 1332-1341.
99. Jain RK (2001) Normalizing tumor vasculature with antiangiogenic therapy, a new paradigm for combination therapy. Nat Med 7, 987-989.
100. Jiemjit A, Fandy TE, Carraway H, Bailey KA, Baylin S, Herman JG, Gore SD (2008) p21(WAF1/CIP1) induction by 5-azacytosine nucleosides requires DNA damage. Oncogene., in press.
101. Jordan MA, Kamath K, Manna T, Okouneva T, Miller HP, Davis C, Littlefield BA, Wilson L (2005) The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 4, 1086-1095.
102. Kainthan RK, Mugabe C, Burt HM, Brooks DE (2008) Unimolecular micelles based on hydrophobically derivatized hyperbranched polyglycerols, ligand binding properties. Biomacromolecules 9, 886-895.
103. Kamath K, Jordan MA (2003) Suppression of Microtubule Dynamics by Epothilone B Is Associated with Mitotic Arrest. Cancer Res 63, 6026 - 6031.
104. Kanai M, Tong WM, Wang ZQ, Miwa M (2007) Haploinsufficiency of poly(ADP-ribose) polymerase-1-mediated poly(ADP-ribosyl)ation for centrosome duplication. Biochem Biophys Res Commun 359, 426-430.
105. Kanoh K, Kohno S, Katada J, Hayashi Y, Muramatsu M, Uno I (1999) Antitumor Activity of Phenylahistin in Vitro and in Vivo Biosci Biotechnol Biochem 63, 1130-1133
106. Karmali PP, Kotamraju VR, Kastantin M, Black M, Missirlis D, Tirrell M, Ruoslahti E (2008) Targeting of albuminembedded paclitaxel nanoparticles to tumors. Nanomedicine NBM, in press.
107. Katada J., Muramatsu M., Kawashima H., Sekiya H., Uno I (1997) (-)-Phenylahistin, A New Mammalian Cell Cycle Inhibitor Produced By Aspergillus Ustus Bioorg Med Chem Lett 22, 2847-2852.
108. Keating TJ, Peloquin JG, Rodionov VI, Momcilovic D, Borisy GG (1997) Microtubule release from the centrosome. Proc Natl Acad Sci U S A. 94, 5078-5083.
109. Kenneth, DT (2005) TLK-286, a novel glutathione S-transferaseactivated prodrug. Expert Opin Investig Drugs 14, 1047-54.
110. Khaddor M, Saidi R, Aidoun A, Lamarti A, Tantaoui-Elaraki A, Ezziyyani M, Candela Castillo M-E, Badoc A (2007) Antibacterial effects and toxigenesis of Penicillium aurantiogriseum and P. viridicatum African Journal of Biotechnology 6 (20), 2314-2318.
111. Khalil MW, Sasse F, Lünsdorf H, Elnakady YA, Reichenbach H (2006) Mechanism of action of tubulysin, an antimitotic peptide from myxobacteria. Chembiochem 7, 678-683.
112. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844.
113. Kim TJ, Lim Y, Kim DW, Kwon JS, Son JH, Jin YR, Son DJ, Jung JC, Avery MA, Hong JT, Yun YP (2007) Epothilone D, a microtubule-stabilizing compound, inhibits neointimal hyperplasia after rat carotid artery injury by cell cycle arrest via regulation of G1-checkpoint proteins. Vascul Pharmacol 47, 229-237.
114. Kindler HL, Tothy PK, Wolff R, McCormack RA, Abbruzzese JL, Mani S, Wade-Oliver KT, Vokes EE (2005) Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers. Invest New Drugs 23, 489-493.
115. Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, Bhatia R (2008) Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia., in press.
116. Kontoyianni C, Sideratou Z, Theodossiou T, Tziveleka LA, Tsiourvas D, Paleos CM (2008) A novel micellar PEGylated hyperbranched polyester as a prospective drug delivery system for paclitaxel. Macromol Biosci 8, 871-881.
117. Koshkina NV, Waldrep JC, Roberts LE, Golunski E, Melton S, Knight V (2001) Paclitaxel liposome aerosol treatment induces inhibition of pulmonary metastases in murine renal carcinoma model. Clin Cancer Res 7, 3258-3262.
118. Koukoulitsa C, Kyrikou I, Demetzos C, Mavromoustakos T (2006) The role of the anticancer drug vinorelbine in lipid bilayers using differential scanning calorimetry and molecular modeling. Chem Phys Lipids 144, 85-95.
119. Kurata T, Shimada Y, Tamura T, Yamamoto N, Hyodo I, Saeki T, Takashima S, Fujiwara K, Wakasugi H, Kashimura M (2000) Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J Clin Oncol 18, 3164-3171.
120. Lacko AG, Nair M, Prokai L, McConathy WJ (2007) Prospects and challenges of the development of lipoprotein-based formulations for anti-cancer drugs. Expert Opin Drug Deliv 4, 665-675.
121. Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH (2007) Eastern Cooperative Oncology Group, Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 Non-small-cell lung cancer patients, ECOG 1599. J Clin Oncol 25, 418-423.
122. Larkin JM, Kaye SB (2006) Epothilones in the treatment of cancer. Expert Opin Investig Drugs 15, 691-702.
123. Larsen TO, Frisvad JC, Jensen SR (1992) Aurantiamine, A Diketopiperazine from Two Varieties of Penicillium Aurantiogriseum Phytochemistry 31, 1613-1615
124. Le Tourneau C, Raymond E, Faivre S (2007) Aplidine, a paradigm of how to handle the activity and toxicity of a novel marine anticancer poison. Curr Pharm Des 13, 3427-3439.
125. Lee H, Lee K, Park TG (2008) Hyaluronic acid-paclitaxel conjugate micelles, synthesis, characterization, and antitumor activity. Bioconjug Chem 19, 1319-1325.
126. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 1, 1633-1642.
127. Lee SC, Huh KM, Lee J, Cho YW, Galinsky RE, Park K (2007) Hydrotropic polymeric micelles for enhanced paclitaxel solubility, in vitro and in vivo characterization. Biomacromolecules 8, 202-208.
128. Lee SH, Son SM, Son DJ, Kim SM, Kim TJ, Song S, Moon DC, Lee HW, Ryu JC, Yoon DY, Hong JT (2007) Epothilones induce human colon cancer SW620 cell apoptosis via the tubulin polymerization independent activation of the nuclear factor-kappaB/IkappaB kinase signal pathway. Mol Cancer Ther 6, 2786-2797.
129. Lee Villano J, Mehta D, Radhakrishnan L (2006) Abraxane induced life-threatening toxicities with metastatic breast cancer and hepatic insufficiency. Invest New Drugs 24, 455-456.
130. Li C, Newman RA, Wu QP, Ke S, Chen W, Hutto T, Kan Z, Brannan MD, Charnsangavej C, Wallace S (2000) Biodistribution of paclitaxel and poly(l -glutamic acid)-paclitaxel conjugate in mice with ovarian OCa-1 tumor. Cancer Chemother Pharmacol 46, 416-422.
131. Li J, Chen F, Hu C, He L, Yan K, Zhou L, Pan W (2008) Optimized preparation of in situ forming microparticles for the parenteral delivery of vinpocetine. Chem Pharm Bull (Tokyo) 56, 796-801.
132. Lim Y, Kim TJ, Jin YR, Kim DW, Kwon JS, Son JH, Jung JC, Avery MA, Son DJ, Hong JT, Yun YP (2007) Epothilone B inhibits neointimal formation after rat carotid injury through the regulation of cell cycle-related proteins. J Pharmacol Exp Ther 321, 648-655.
133. Lin NU, Parker LM, Come SE, Burstein HJ, Haldoupis M, Ryabin N, Gelman R, Winer EP, Shulman LN (2007) Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer, unexpected incidence of hypersensitivity reactions Invest New Drugs 25, 369-375
134. Liu B, Yang M, Li X, Qian X, Shen Z, Ding Y, Yu L (2008) Enhanced efficiency of thermally targeted taxanes delivery in a human xenograft model of gastric cancer. J Pharm Sci 97, 3170-3181.
135. Lobo C, Lopes G, Silva O, Gluck S (2007) Paclitaxel albuminbound particles (abraxane) in combination with bevacizumab with or without gemcitabine, early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed Pharmacother 61, 531-533.
136. Luo L, Xu X, Shi B, Wu J, Hu Y (2007) Polyoxyethylene 40 stearate modulates multidrug resistance and enhances antitumor activity of vinblastine sulfate. AAPS J 9, E329-35.
137. Luo Y, Chen D, Ren L, Zhao X, Qin J (2006) Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability. J Control Release 114, 53-59.
138. Mackler NJ, Pienta KJ (2005) Drug insight, Use of docetaxel in prostate and urothelial cancers. Nat Clin Pract Urol 2, 92-100.
139. Magnani M, Ortuso F, Soro S, Alcaro S, Tramontano A, Botta M (2006) The βI/βIII-tubulin isoforms and their complexes with antimitotic agents. Docking and molecular dynamics studies. FEBS J 273, 3301-3310.
140. Makarov AA, Tsvetkov PO, Villard C, Esquieu D, Pourroy B, Fahy J, Braguer D, Peyrot V, Lafitte D (2007) Vinflunine, a novel microtubule inhibitor, suppresses calmodulin interaction with the microtubule-associated protein STOP. Biochemistry. 46, 14899-14906.
141. Marguerite V, Beri-Dexheimer M, Ortiou S, Guéant JL, Merten M (2007) Cobalamin potentiates vinblastine cytotoxicity through downregulation of mdr-1 gene expression in HepG2 cells. Cell Physiol Biochem 20, 967-976.
142. McConathy WJ, Nair MP, Paranjape S, Mooberry L, Lacko AG (2008) Evaluation of synthetic/reconstituted high-density lipoproteins as delivery vehicles for paclitaxel. Anticancer Drugs 19, 183-188.
143. McKeown SR, Cowen RL, Williams KJ (2007) Bioreductive drugs, from concept to clinic. Clin Oncol (R Coll Radiol) 19, 427-442.
144. Meerum Terwogt JM, ten Bokkel Huinink WW, Schellens JH, Schot M, Mandjes IA, Zurlo MG, Rocchetti M, Rosing H, Koopman FJ, Beijnen JH (2001) Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel. Anticancer Drugs 12, 315-323.
145. Miller JH, Wilmes A, Bargh K, Kelly C, Northcote PT (2007) Peloruside A Synergizes with Other Microtubule Stabilizing Agents in Cultured Cancer Cell Lines. Mol Pharm. 4, 269-280.
146. Moneo V, Serelde BG, Leal JF, Blanco-Aparicio C, Diaz-Uriarte R, Aracil M, Tercero JC, Jimeno J, Carnero A (2007) Levels of p27(kip1) determine Aplidin sensitivity. Mol Cancer Ther 6, 1310-1316.
147. Mooberry SL (2007) Strategies for the development of novel Taxol-like agents. Methods Mol Med 137, 289-302.
148. Moreno-Aspitia A, Perez EA (2005) Nanoparticle albuminbound paclitaxel (ABI-007), a newer taxane alternative in breast cancer. Future Oncol 1, 755-762.
149. Morgan MA, Darcy KM, Rose PG, DeGeest K, Bookman MA, Aikins JK, Sill MW, Mannel RS, Allievi C, Egorin MJ (2008) Gynecologic Oncology Group.
150. Moser C, Lang SA, Mori A, Hellerbrand C, Schlitt HJ, Geissler EK, Fogler WE, Stoeltzing O (2008) ENMD-1198, a novel tubulin-binding agent reduces HIF-1alpha and STAT3 activity in human hepatocellular carcinoma(HCC) cells, and inhibits growth and vascularization in vivo. BMC Cancer 23, 206.
151. Murata-Hori M, Tatsuka M, Wang YL (2002) Probing the dynamics and functions of aurora B kinase in living cells during mitosis and cytokinesis. Mol Biol Cell 13, 1099-1108.
152. Nagano S, Li H, Shimizu H, Nishida C, Ogura H, Ortiz de Montellano PR, Poulos TL (2003) Crystal structures of epothilone D-bound, epothilone B-bound, and substrate-free forms of cytochrome P450epoK. J Biol Chem 278, 44886-44893.
153. Nakano H, Nakamura Y, Soda H, Kamikatahira M, Uchida K, Takasu M, Kitazaki T, Yamaguchi H, Nakatomi K, Yanagihara K, Kohno S, Tsukamoto K (2008) Methylation status of breast cancer resistance protein detected by methylation-specific polymerase chain reaction analysis is correlated inversely with its expression in drug-resistant lung cancer cells. Cancer. 112, 1122-1130.
154. Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, Matsumura Y (2006) NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer 95, 601-606.
155. Nemunaitis J, Cunningham C, Senzer N, Gray M, Oldham F, Pippen J, Mennel R, Eisenfeld A (2005) Phase I study of CT-2103, a polymer-conjugated paclitaxel, and carboplatin in patients with advanced solid tumors. Cancer Invest 23, 671-676.
156. Nguyen L, Bennouna J, Delord JP, Campone M (2008) Vinflunine, a new microtubule inhibitor agent. Clin Cancer Res 14, 1625-1632.
157. Nomura M, Inoue Y, Fujita S, Sakao J, Hirota M, Souda S, Ohshima M (2005) Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. Breast Cancer 12, 226-230.
158. Nyman DW, Campbell KJ, Hersh E, Long K, Richardson K, Trieu V, Desai N, Hawkins MJ, Von Hoff DD (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23, 7785-7793.
159. O'Brien ME, Socinski MA, Popovich AY, Bondarenko IN, Tomova A, Bilynsky BT, Hotko YS, Ganul VL, Kostinsky IY, Eisenfeld AJ, Sandalic L, Oldham FB, Bandstra B, Sandler AB, Singer JW (2008) Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer. J Thorac Oncol 3, 728-734.
160. O'Dwyer PJ (2006) The present and future of angiogenesisdirected treatments of colorectal cancer. Oncologist. 1, 992-998.
161. Oldham EA, Li C, Ke S, Wallace S, Huang P (2000) Comparison of action of paclitaxel and poly(L-glutamic acid)-paclitaxel conjugate in human breast cancer cells. Int J Oncol 16, 125-132.
162. Panda D, Miller HP, Islam K, Wilson L (1997) Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin, a possible mechanistic basis for its antitumor action. Proc Natl Acad Sci U S A 94, 10560-10564.
163. Panda D, Rathinasamy K, Santra MK, Wilson L (2005) Kinetic suppression of microtubule dynamic instability by griseofulvin, implications for its possible use in the treatment of cancer Proc Natl Acad Sci USA 102, 9878-9883
164. Papadopoulou MV, Ji X, Bloomer WD (2006) Potentiation of alkylating agents by NLCQ-1 or TPZ in vitro and in vivo. J Exp Ther Oncol 5, 261-272.
165. Pappo AS, Lyden E, Breitfeld P, Donaldson SS, Wiener E, Parham D, Crews KR, Houghton P, Meyer WH (2007) Children's Oncology Group, Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma, the Children's Oncology Group. J Clin Oncol 25, 362-369.
166. Park WS, Park SJ, Han SJ, Lee J, Kim DS, Kim JH, Kim BW, Lee J, Sim SJ (2007) Repeated batch production of epothilone B by immobilized Sorangium cellulosum. J Microbiol Biotechnol 17, 1208-1212.
167. Parker KA, Wang P (2007) Deconstruction-reconstruction strategy for accessing valuable polyketides. Preparation of the C15-C24 stereopentad of discodermolide. Org Lett 9, 4793-4796.
168. Pasquier E, Kavallaris M (2008) Microtubules, a dynamic target in cancer therapy. IUBMB Life 60, 165-170.
169. Patel S, Keohan ML, Saif MW, Rushing D, Baez L, Feit K, DeJager R, Anderson S (2006) Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy. Cancer 107, 2881-2887.
170. Paterson I, Gardner NM, Poullennec KG, Wright AE (2008) Synthesis and Biological Evaluation of 10,11-Dihydrodictyostatin, a Potent Analogue of the Marine Anticancer Agent Dictyostatin. J Nat Prod 71, 364-369.
171. Paz-Ares L, Ross H, O'Brien M, Riviere A, Gatzemeier U, Von Pawel J, Kaukel E, Freitag L, Digel W, Bischoff H, García-Campelo R, Iannotti N, Reiterer P, Bover I, Prendiville J, Eisenfeld AJ, Oldham FB, Bandstra B, Singer JW, Bonomi P (2008) Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. Br J Cancer 98, 1608-1613.
172. Perez EA (2007) Novel enhanced delivery taxanes, an update. Semin Oncol 34, suppl 1-5.
173. Perez EA, Hillman DW, Fishkin PA, Krook JE, Tan WW, Kuriakose PA, Alberts SR, Dakhil SR (2005) Phase II trial of dolastatin-10 in patients with advanced breast cancer. Invest New Drugs 23, 257-261.
174. Petit I, Karajannis MA, Vincent L, Young L, Butler J, Hooper AT, Shido K, Steller H, Chaplin DJ, Feldman E, Rafii S (2008) The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death. Blood 111, 1951-1961.
175. Posadas EM, Undevia S, Manchen E, Wade JL, Colevas AD, Karrison T, Vokes EE, Stadler WM (2007) A phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma Cancer Biol Ther 6, 490-493
176. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, Winkler M, Ferrara N (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57, 4593-4599.
177. Pronzato P (2008) New therapeutic options for chemotherapyresistant m etastatic breast cancer, the epothilones. Drugs 68, 139-146.
178. Puissant A, Grosso S, Jacquel A, Belhacene N, Colosetti P, Cassuto JP, Auberger P (2008) Imatinib mesylate-resistant human chronic myelogenous leukemia cell lines exhibit high sensitivity to the phytoalexin resveratrol. FASEB J, in press.
179. Markers predicting clinical benefit in breast cancer from microtubule-targeting agents
180. Pyrko P, Schönthal AH, Hofman FM, Chen TC, Lee AS (2007) The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res 67, 9809-9816.
181. Quaglia F, Ostacolo L, Mazzaglia A, Villari V, Zaccaria D, Sciortino MT (2009) The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials 30, 374-382.
182. Rana S, Maples PB, Senzer N, Nemunaitis J (2008) Stathmin 1, a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 8, 1461-1470.
183. Ranieri G, Patruno R, Ruggieri E, Montemurro S, et al (2006) Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer, from the biology to the clinic. Curr Med Chem 13, 1845-1857.
184. Ranson M, Thatcher N (1999) Paclitaxel, a hope for advanced non-small cell lung cancer? Expert Opin Investig Drugs 8, 837-848
185. Reichenbach H, Höfle G (2008) Discovery and development of the epothilones, a novel class of antineoplastic drugs. Drugs R D 9, 1-10.
186. Richards DA, Richards P, Bodkin D, Neubauer MA, Oldham F (2005) Efficacy and safety of paclitaxel poliglumex as firstline chemotherapy in patients at high risk with advancedstage non-small-cell lung cancer, results of a phase II study. Clin Lung Cancer 7, 215-220.
187. Riely GJ, Gadgeel S, Rothman I, Saidman B, Sabbath K, Feit K, Kris MG, Rizvi NA (2007) A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy. Lung Cancer 55, 181-185.
188. Rodionov V, Nadezhdina E, Borisy G (1999) Centrosomal control of microtubule dynamics. Proc Natl Acad Sci U S A 96, 115-120.
189. Roncuzzi L, Marti G, Baiocchi D, Del Coco R, Cocchi S, Gasperi-Campani A (2006) Effect of Vinorelbine on cell growth and apoptosis induction in human osteosarcoma in vitro. Oncol Rep 15, 73-77.
190. Rose WC, Fairchild C, Lee FY (2001) Preclinical antitumor activity of two novel taxanes. Cancer Chemother Pharmacol 47, 97-105.
191. Rothenberg M, Hande K, Nabulsi A, Berlin J, Meek K, Roth B, Lockhart C, Glad-Anderson S, Eliopoulos H, Roberts P (2002) A phase I trial of ABT-751, a novel microtubulin inhibitor Eur J Cancer 38, S.7, S42.
192. Rowinsky EK, Calvo E (2006) Novel agents that target tublin and related elements. Semin Oncol 33, 421-435.
193. Ruffié P, Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H, Cadic V, Pinel MC, Rivière A, Ollivier L (2007) Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 25, 4751-4756.
194. Safavy A (2008) Recent developments in taxane drug delivery. Curr Drug Deliv 5, 42-54.
195. Sarris AH, Hagemeister F, Romaguera J, Rodriguez MA, McLaughlin P, Tsimberidou AM, Medeiros LJ, Samuels B, Pate O, Oholendt M, Kantarjian H, Burge C, Cabanillas F (2000) Liposomal vincristine in relapsed non-Hodgkin's lymphomas, early results of an ongoing phase II trial. Ann Oncol 11, 69-72.
196. Sato B, Nakajima H, Hori Y, Hino M, Hashimoto S, Terano H (2000) A new antimitotic substance, FR182877. II. The mechanism of action. J Antibiot (Tokyo) 53, 123-130.
197. Saville M, Lietzau J, Pluda J, Feuerstein I, Odom J, Wilson W, Humphrey R, Feigal E, Steinberg S, Broder S (1995) Treatment of HIV-associated Kaposi's sarcoma with paclitaxel. Lancet 346, 26-28.
198. Schelman W, Morgan-Meadows S, Bailey H, Holen K, Thomas JP, Eickhoff J, Brandon H, Oliver K, Alberti D, Wilding G (2008) A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors. Cancer Chemother Pharmacol, in press.
199. Senthilkumar M, Mishra P, Jain NK (2008) Long circulating PEGylated poly(D,L-lactide-co-glycolide) nanoparticulate delivery of Docetaxel to solid tumors. J Drug Target 16, 424-435.
200. Serafin AM, Bohm L (2005) Influence of p53 and bcl-2 on chemosensitivity in benign and malignant prostatic cell lines. Urol Oncol 23, 123-129.
201. Sessa C, Cuvier C, Caldiera S, Bauer J, Van Den Bosch S, Monnerat C, Semiond D, Pérard D, Lebecq A, Besenval M, Marty M (2002) Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann Oncol 13, 1140-1150.
202. Shang D, Ito N, Kamoto T, Ogawa O (2007) Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of renal cell carcinoma to paclitaxel. Urology 69, 1007-1012.
203. Shaw SJ, Menzella HG, Myles DC, Xian M, Smith AB 3rd (2007) Coumarin-derived discodermolide analogues possessing equivalent antiproliferative activity to the natural product--a further simplification of the lactone region. Org Biomol Chem 5, 2753-2755.
204. Shnyder SD, Hasan J, Cooper PA, Pilarinou E, Jubb E, Jayson GC, Bibby MC (2005) Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature Anticancer Res 25, 1889-1894
205. Simoens C, Lardon F, Pauwels B, De Pooter CM, Lambrechts HA, Pattyn GG, Breillout F, Vermorken JB (2008) Comparative study of the radiosensitizing and cell cycle effects of vinflunine and vinorelbine, in vitro. BMC Cancer 8, 65.
206. Simoens C, Vermorken JB, Korst AE, Pauwels B, De Pooter CM, Pattyn GG, Lambrechts HA, Breillout F, Lardon F (2006) Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro. Cancer Chemother Pharmacol 58, 210-218.
207. Smedsgaard J., Frisvad, J. C (1996) Using direct electrospray mass spectrometry in taxonomy and secondary metabolite profiling of crude fungal extracts. J Microbiol Meth 25, 5-17.
208. Song X, Zhao Y, Hou S, Xu F, Zhao R, He J, Cai Z, Li Y, Chen Q (2008) Dual agents loaded PLGA nanoparticles, systematic study of particle size and drug entrapment efficiency. Eur J Pharm Biopharm 69, 445-453.
209. Sonpavde G, Galsky MD, Hutson TE (2008) Current optimal chemotherapy for advanced urothelial cancer. Expert Rev Anticancer Ther 8, 51-61.
210. Spano A, Monaco G, Barni S, Sciola L (2007) Expression of cell kinetics and death during monocyte-macrophage differentiation, effects of Actinomycin D and Vinblastine treatments. Histochem Cell Biol 127, 79-94.
211. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N (2005) Comparative preclinical and clinical pharmacokinetics of a cremophor-free, nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol) Clin Cancer Res 11, 4136-4143
212. Srivastana RK, Srivastana AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS, Longo DL (1998) Involvement of Microtubules in the Regulation of Bcl2 Phosphorylation and Apoptosis through Cyclic AMP-Dependent Protein Kinase Mol Cell Biol 18, 3509-3517
213. Stachel SJ, Chappell MD, Lee CB, Danishefsky SJ, Chou TC, He L, Horwitz SB (2000) On the total synthesis and preliminary biological evaluations of 15(R) and 15(S) aza-dEpoB, a Mitsunobu inversion at C15 in pre-epothilone fragments. Org Lett 2, 1637-1639.
214. Stinchcombe TE, Socinski MA, Walko CM, O'Neil BH, Collichio FA, Ivanova A, Mu H, Hawkins MJ, Goldberg RM, Lindley C, Claire Dees E (2007) Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 60, 759-766.
215. Strube A, Stepina E, Klar U, Hauff P, Hoffmann J, Käkönen S-M (2008) Sagopilone (ZK-EPO) inhibits bone destruction and tumor burden more efficiently than paclitaxel in a mouse model of established breast cancer bone metastasis Bone 42 Suppl 1, 108
216. Sun W, Stevenson JP, Gallagher ML, Vaughn D, Hahn SM, Haller DG, Cohen M, Kopit J, Gallant G, O'Dwyer PJ (2003) Phase I and pharmacokinetic trial of the novel taxane BMS-184476 administered as a 1-hour intravenous infusion in combination with cisplatin every 21 days. Clin Cancer Res 9, 5221-5227.
217. Sznitowska M, Klunder M, Placzek M (2008) Paclitaxel solubility in aqueous dispersions and mixed micellar solutions of lecithin. Chem Pharm Bull (Tokyo) 56, 70-74.
218. Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H, Cadic V, Pinel MC, Rivière A, Ollivier L, Ruffié P (2007) Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 25, 4751-4756.
219. Tamura K, Nakagawa K, Kurata T, Satoh T, Nogami T, Takeda K, Mitsuoka S, Yoshimura N, Kudoh S, Negoro S, Fukuoka M (2007) Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses. Cancer Chemother Pharmacol 60, 285-293.
220. Teicher BA, Forler P, Menon K, Phares V, Amsrud T, Shih C (2000) Cryptophycin 52 and cryptophycin 55 in sequential and simultaneous combination treatment regimens in human tumor xenografts. In Vivo 14, 471-480.
221. To KK, Polgar O, Huff LM, Morisaki K, Bates SE (2008) Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells. Mol Cancer Res 6, 151-164.
222. Torres K, Horwitz SB (1998) Mechanisms of Taxol-induced Cell Death Are Concentration Dependent. Cancer Res 58, 3620-3626.
223. Van Tol BL, Missan S, Crack J, Moser S, Baldridge WH, Linsdell P, Cowley EA (2007) Contribution of KCNQ1 to the regulatory volume decrease in the human mammary epithelial cell line MCF-7 Am J Physiol Cell Physiol 293, C1010-1019
224. Vanderwal CD, Vosburg DA, Weiler S, Sorensen EJ (1999) Postulated biogenesis of WS9885B and progress toward an enantioselective synthesis. Org Lett 1, 645-648.
225. Velcheti V, Viswanathan A, Govindan R (2006) The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with bevacizumab, a single institutional survey J Thorac Oncol 1, 501
226. Verbeek B, Southgate TD, Gilham DE, Margison GP (2008) O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 85, 17-33.
227. Veronese ML, Flaherty K, Kramer A, Konkle BA, Morgan M, Stevenson JP, O'Dwyer PJ (2005) Phase I study of the novel taxane CT-2103 in patients with advanced solid tumors. Cancer Chemother Pharmacol 55, 497-501.
228. Villalonga N, Ferreres JC, Argilés JM, Condom E, Felipe A (2007) Potassium channels are a new target field in anticancer drug design. Recent Patents Anticancer Drug Discov 2, 212-223.
229. von Mehren M, Balcerzak SP, Kraft AS, Edmonson JH, Okuno SH, Davey M, McLaughlin S, Beard MT, Rogatko A (2004) Phase II Trial of Dolastatin-10, a Novel Anti-Tubulin Agent, in Metastatic Soft Tissue Sarcomas. Sarcoma 8, 107-111.
230. Wan F, You J, Sun Y, Zhang XG, Cui FD, Du YZ, Yuan H, Hu FQ (2008) Studies on PEG-modified SLNs loading vinorelbine bitartrate (I), preparation and evaluation in vitro. Int J Pharm 359, 104-10.
231. Wang C, Cormier A, Gigant B, Knossow M (2007) Insight into the GTPase activity of tubulin from complexes with stathmin-like domains. Biochemistry 46, 10595-10602.
232. Wang FP, Wang L, Yang JS, Nomura M, Miyamoto K (2005) Reversal of P-glycoprotein-dependent resistance to vinblastine by newly synthesized bisbenzylisoquinoline alkaloids in mouse leukemia P388 cells. Biol Pharm Bull 28, 1979-1982.
233. Wang Y, Yu L, Han L, Sha X, Fang X (2007) Difunctional Pluronic copolymer micelles for paclitaxel delivery, synergistic effect of folate-mediated targeting and Pluronicmediated overcoming multidrug resistance in tumor cell lines. Int J Pharm 337(1-2), 63-73.
234. Wang YC, Liu XQ, Sun TM, Xiong MH, Wang J (2008) Functionalized micelles from block copolymer of polyphosphoester and poly(ε-caprolactone) for receptormediated drug delivery. J Control Release. 128, 32-40.
235. Wang YC, Tang LY, Sun TM, Li CH, Xiong MH, Wang J (2008) Self-assembled micelles of biodegradable triblock copolymers based on poly(ethyl ethylene phosphate) and poly(ε-caprolactone) as drug carriers. Biomacromolecules 9, 388-395.
236. Wender PA, Verma VA, Paxton TJ, Pillow TH (2008) Functionoriented synthesis, step economy, and drug design. Acc Chem Res 41, 40-49.
237. Wilmes A, Bargh K, Kelly C, Northcote PT, Miller JH (2007) Peloruside A synergizes with other microtubule stabilizing agents in cultured cancer cell lines. Mol Pharm 4, 269-280.
238. Wright AE, Isbrucker RA, Cummins J, Pomponi SA, Longley RE (2003) Tubulin polymerizing activity of dictyostatin-1, a polyketide of marine sponge origin. Biochem Pharmacol 66, 75-82.
239. Wu J, Meng F, Lu H, Kong L, Bornmann W, Peng Z, Talpaz M, Donato NJ (2008) Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib resistant chronic myelogenous leukemia cells. Blood. 111, 3821-3829.
240. Xia S, Kenesky CS, Rucker PV, Smith AB 3rd, Orr GA, Horwitz SB (2006) A photoaffinity analogue of discodermolide specifically labels a peptide in β-tubulin. Biochemistry 45, 11762-11775.
241. Xu Z, Chen L, Gu W, Gao Y, Lin L, Zhang Z, Xi Y, Li Y (2009) The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma. Biomaterials 30, 226-232.
242. Yarosh W, Barrientos T, Esmailpour T, Lin L, Carpenter PM, Osann K, Anton-Culver H, Huang T (2008) TBX3 is overexpressed in breast cancer and represses p14 ARF by interacting with histone deacetylases. Cancer Res 68, 693-699.
243. Yin LT, Fu YJ, Xu QL, Yang J, Liu ZL, Liang AH, Fan XJ, Xu CG (2007) Potential biochemical therapy of glioma cancer. Biochem Biophys Res Commun 362, 225-229.
244. Yin S, Cabral F, Veeraraghavan S (2007) Amino acid substitutions at proline 220 of β-tubulin confer resistance to paclitaxel and colcemid. Mol Cancer Ther 6, 2798-2806.
245. Yoo GH, Tran VR, Lemonnier LA, Ezzat WH, Subramanian G, Piechocki MP, Ensley JF, Lonardo F, Kim H, Lin HS (2007) BMS-275183-induced gene expression patterns in head and neck carcinoma. Am J Otolaryngol 28, 309-315.
246. You J, Wan F, de Cui F, Sun Y, Du YZ, Hu FQ (2007) Preparation and characteristic of vinorelbine bitartrate-loaded solid lipid nanoparticles. Int J Pharm 343, 270-276.
247. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M (2001) Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 92, 2267-2272.
248. Zhang LH, Wu L, Raymon HK, Chen RS, Corral L, Shirley MA, Narla RK, Gamez J, Muller GW, Stirling DI, Bartlett JB, Schafer PH, Payvandi F (2006) The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-alpha production with antitumor activity. Cancer Res 66, 951-959.
249. Zhang X, Burt HM, Mangold G, Dexter D, Von Hoff D, Mayer L, Hunter WL (1997) Anti-tumor efficacy and biodistribution of intravenous polymeric micellar paclitaxel. Anticancer Drugs 8, 696-701.